29-mRNA宿主反应全血特征可改善急诊疑似急性感染和/或脓毒症成人28天死亡率和7天ICU治疗的预测
研究前瞻性验证29-mRNA宿主反应分类器IMX-SEV-2对急诊疑似急性感染和/或脓毒症成人严重程度的预测价值。在希腊6个急诊科纳入397名成人,38人(9.6%)在28天内死亡。IMX-SEV-2预测28天死亡率AUC为0.82(95%CI 0.74-0.90),优于乳酸(0.66)、降钙素原(0.67),与qSOFA(0.81)相当;与qSOFA联合后准确率提升至0.89(95%CI 0.82-0.96)。高严重度(rule-in)带预测28天死亡率特异性96.9%,低严重度(rule-out)带敏感性78.9%;IMX-SEV-2也能准确预测7天ICU治疗需求,与qSOFA联合进一步提高总体准确率。
要点
- IMX-SEV-2预测28天死亡率AUC 0.82(95%CI 0.74-0.90),优于乳酸0.66(95%CI 0.54-0.77)和降钙素原0.67(95%CI 0.57-0.78),与qSOFA 0.81(95%CI 0.72-0.89)相当。
- qSOFA联合IMX-SEV-2将预测28天死亡率的准确率从0.81提升至0.89(95%CI 0.82-0.96)。
- IMX-SEV-2高严重度(rule-in)带预测28天死亡率特异性96.9%,低严重度(rule-out)带敏感性78.9%。
- IMX-SEV-2单独即可准确预测7天ICU治疗需求,与qSOFA联合进一步提高总体准确率。
- 研究纳入397名急诊疑似急性感染且至少一项生命体征异常的成人,28天死亡率9.6%(38/397)。
适用人群与场景
- 急诊科成人患者,疑似急性感染和/或疑似脓毒症,且至少一项生命体征异常;研究在希腊6个急诊科纳入。
诊断标准与关键阈值
- IMX-SEV-2分类器将风险评分分为低、中、高严重度三个解释带;高严重度(rule-in)带预测28天死亡率特异性96.9%,低严重度(rule-out)带敏感性78.9%。
研究设计与关键结果
- 前瞻性验证研究,纳入397名急诊疑似急性感染且至少一项生命体征异常的成人,38人(9.6%)在28天内死亡。
- IMX-SEV-2预测28天死亡率AUC 0.82(95%CI 0.74-0.90),乳酸AUC 0.66(95%CI 0.54-0.77),降钙素原AUC 0.67(95%CI 0.57-0.78),qSOFA AUC 0.81(95%CI 0.72-0.89)。
- qSOFA联合IMX-SEV-2将预测28天死亡率的准确率从0.81提升至0.89(95%CI 0.82-0.96)。
- IMX-SEV-2高严重度(rule-in)带预测28天死亡率特异性96.9%,低严重度(rule-out)带敏感性78.9%。
- IMX-SEV-2单独可准确预测7天ICU治疗需求,与qSOFA联合进一步提高总体准确率。
证据类型、等级与局限
- 证据类型:前瞻性验证研究;局限:原文未报告局限性。
对床旁实践的改变
- 在急诊疑似急性感染和/或脓毒症成人中,IMX-SEV-2可预测28天死亡率和7天ICU治疗需求,与qSOFA联合可提高预测准确率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Risk stratification of emergency department patients with suspected acute infections and/or suspected sepsis remains challenging. We prospectively validated a 29-messenger RNA host response classifier for predicting severity in these patients. Methods: We enrolled adults presenting with suspected acute infections and at least one vital sign abnormality to six emergency departments in Greece. Twenty-nine target host RNAs were quantified on NanoString nCounter and analyzed with the Inflammatix Severity 2 (IMX-SEV-2) classifier to determine risk scores as low, moderate, and high severity. Performance of IMX-SEV-2 for prediction of 28-day mortality was compared with that of lactate, procalcitonin, and quick sequential organ failure assessment (qSOFA). Results: A total of 397 individuals were enrolled; 38 individuals (9.6%) died within 28 days. Inflammatix Severity 2 classifier predicted 28-day mortality with an area under the receiver operator characteristics curve of 0.82 (95% confidence interval [CI], 0.74-0.90) compared with lactate, 0.66 (95% CI, 0.54-0.77); procalcitonin, 0.67 (95% CI, 0.57-0.78); and qSOFA, 0.81 (95% CI, 0.72-0.89). Combining qSOFA with IMX-SEV-2 improved prognostic accuracy from 0.81 to 0.89 (95% CI, 0.82-0.96). The high-severity (rule-in) interpretation band of IMX-SEV-2 demonstrated 96.9% specificity for predicting 28-day mortality, whereas the low-severity (rule-out) band had a sensitivity of 78.9%. Similarly, IMX-SEV-2 alone accurately predicted the need for day-7 intensive care unit care and further boosted overall accuracy when combined with qSOFA. Conclusions: Inflammatix Severity 2 classifier predicted 28-day mortality and 7-day intensive care unit care with high accuracy and boosted the accuracy of clinical scores when used in combination.
参考来源
- Kostaki A, Wacker JW, Safarika A, et al. A 29-MRNA HOST RESPONSE WHOLE-BLOOD SIGNATURE IMPROVES PREDICTION OF 28-DAY MORTALITY AND 7-DAY INTENSIVE CARE UNIT CARE IN ADULTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH SUSPECTED ACUTE INFECTION AND/OR SEPSIS. Shock. 2022. PMID: 36125356. doi:10.1097/SHK.0000000000001970
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。